Overview

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Status:
RECRUITING

Trial end date:
2027-03-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

Phase:

PHASE3

Details

Lead Sponsor:

Pfizer

Treatments:

rimegepant sulfate
Standard of Care